SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vector1 who wrote (1892)8/4/1997 4:36:00 PM
From: Vector1   of 9719
 
Yes the road show is going very well indeed. It will probalbly be massively oversubscribed.

Symbol(s) 3888 & Date
Use Page Up, Page Down, +, -, or press U
--------------------------------------------------------------------------------
08/04 4:28P (DJ) =Aviron Up 20% In Response To Road Show Presentations >AVIR
Story 3888 (AVIR, I/BTC, I/MTC, N/DJN, N/DJWI, N/DJS, N/MMM, N/STK, M/TEC...)
NEW YORK (Dow Jones)--Shares of Aviron (AVIR) rose to a 52-week high Monday,
apparently fueled by positive sentiment from company presentations made for a
public offering.
Aviron rose 5 1/4, or 19.6%, to 32 on Nasdaq volume of 1.1 million, compared
with average daily volume of 275,900. The shares traded as high as 32 3/4
earlier, passing the 52-week high of 27 3/4 set just last week.
Sands Brothers & Co. analyst Michael Goldberg said the shares may be
rallying on the strength of Aviron's road show presentations to securities
firms in support of its upcoming public stock offering.
A Robertson Stephens & Co. trader agreed that the shares are probably rising
on the road show presentations, as she did not know of any other reason for
the stock activity.
As reported July 25, Aviron filed with the Securities and Exchange
Commission to offer 2.5 million common shares.
The Mountain View, Calif., biopharmaceutical firm plans to use proceeds for
clinical trials, manufacturing and marketing of its influenza vaccine, and for
research and development. The offering is being managed by Robertson Stephens
& Co.
Goldberg said the company has been making a series of presentations to
attract interest to its offering. Aviron made presentations in Europe last
V1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext